Form 4: Arvinas Director Linda Bain Acquires Shares

Arvinas, Inc. Director Linda Bain acquired restricted stock units and stock options on June 24, 2026, as detailed in a Form 4 filing.

Summary

• Director Linda Bain of Arvinas, Inc. (ARVN) acquired 15,527 shares of common stock on June 24, 2026, through the settlement of restricted stock units (RSUs) granted on the same date.
• These RSUs represent a contingent right to receive one share of common stock upon settlement for no consideration.
• The RSUs are set to vest in full on June 24, 2027, or immediately prior to the first annual stockholder meeting after the grant date, contingent on continued service.
• Additionally, Ms. Bain was granted a stock option on June 24, 2026, giving her the right to buy 22,714 shares of common stock at an exercise price of $8.05 per share.
• This stock option is also scheduled to vest in full on June 24, 2027, or immediately prior to the first annual stockholder meeting after the grant date, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents routine equity awards to a director rather than a significant insider purchase or sale that might signal a strong conviction about the company's immediate prospects.

Positives

• Director Linda Bain has increased her beneficial ownership of Arvinas, Inc. common stock through the acquisition of RSUs and stock options.
• The grant of RSUs and stock options indicates a commitment to aligning management and director interests with shareholder value.
• The RSUs were acquired for no consideration, representing a direct addition to beneficial ownership.

Negatives

• The filing details acquisitions of equity awards rather than open market purchases, which may not reflect direct investment conviction.
• The RSUs and stock options are subject to vesting conditions, meaning the full benefit is contingent on continued service.

Risks

• The vesting of RSUs and stock options is contingent upon the reporting person's continued service with the Issuer, posing a risk of forfeiture if service is terminated before the vesting date.
• The value of the acquired securities is subject to market fluctuations and the future performance of Arvinas, Inc.

Future Outlook

The future outlook for the acquired securities is dependent on the vesting schedule and the continued service of the reporting person, as well as the future performance of Arvinas, Inc.'s common stock.

Industry Context

StockSavvy.ai notes that insider grants of equity awards like RSUs and stock options are common practices in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key personnel, aligning their financial interests with the company's long-term success.

Stakeholder Impact

• Shareholders: The acquisition of equity awards by a director can be viewed positively as it aligns director interests with long-term shareholder value, though it does not represent a direct market purchase.
• Employees: The compensation structure, including equity awards, contributes to employee retention and motivation.
• Management: The grants are part of the compensation package for key management and board members.

Next Steps

• The RSUs and stock options will vest on June 24, 2027, or immediately prior to the first annual meeting of stockholders after the grant date, provided the reporting person continues to be employed by Arvinas, Inc.
• The stock option may be exercised until its expiration date of June 24, 2036.

Key Dates

Keywords

Arvinas, ARVN, Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU, Director, Securities, Equity Awards, Beneficial Ownership